In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management, how AI can reduce startup delays without burdening sites, and how patient-centric drug design is reshaping the CDMO landscape.
A new Applied Clinical Trials contributed analysis of more than 880 clinical trials shows that durability—not speed—is the key differentiator in effective signal management under risk-based quality frameworks. While statistical data monitoring and key risk indicator signals close on similar timelines, SDM signals are far less likely to be reopened. The findings reinforce growing regulatory expectations under ICH E6(R3) for defensible, evidence-based signal closure across the trial lifecycle.
In part 3 of a video interview with Applied Clinical Trials, Brian Mallon of ICON says AI and automation can help address persistent startup delays when applied to reduce administrative burden rather than add complexity. He points to contract tools that surface previously agreed language as practical examples of site-friendly innovation. Mallon emphasizes that operational technology must ultimately serve investigators and patients, preserving the human core of clinical research.
In a PharmTechQ&A, Dr. Asma Patel of Quotient Sciences says the rise of patient-centric drug formulations is driving greater reliance on CDMOs with specialized scientific and manufacturing capabilities. Patel explains that advanced modalities and personalized dosing needs are pushing CDMOs earlier into development, particularly for rare and orphan drugs. As a result, CDMOs are increasingly acting as strategic partners across formulation, scale-up, and regulatory readiness.
In today’s ACT Brief, we examine why AI-enabled trial matching could close the oncology access gap, why IRBs need substantive therapeutic expertise, and how FDA approved Regeneron’s Livsayis, a treatment given four times a year for myasthenia gravis.
In today’s ACT Brief, we examine how trial matching built into standard care can replace reliance on physician memory, how federal funding cuts and FDA staff losses are pressuring biotech, and why FDA is without a commissioner nominee after the White House withdrew Heidi Overton.
In today’s ACT Brief, we examine why oncologists should lead trial discussions while AI supports patients, how site burden can be measured before it becomes risk, and how FDA approved Cosentyx and Wilserdly for two different conditions.
In today’s ACT Brief, we examine how AI can cut coordinator screening time, how participants respond to AI-assisted pre-screening, and how FDA approved three new treatments.
In today’s ACT Brief, we examine what drives inconsistent oncology trial screening, why FDA has reportedly paused its priority voucher pilot, and how patients’ use of AI is reshaping how sponsors communicate with them.
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.